Abstract 6191: Efficacy and Safety Assessment of Anticoagulation Strategies in Peripheral Percutaneous Intervention (original) (raw)

Circulation, 2008

Abstract

Background: Anticoagulation strategies used in peripheral percutaneous intervention (PPI) are based primarily on percutaneous coronary intervention. In these studies, relatively higher doses of heparin were used, usually in combination with a GP IIb/IIIa agent. There are no studies comparing PPIs done with low-dose heparin alone versus bivalirudin in PPI. We compared the efficacy and safety (i.e. bleeding complications) of low-dose heparin versus bivalirudin in PPI. Methods: We assessed prospectively 160 consecutive patients who underwent PPI from January through April 2008 during their index hospitalization for bleeding and thrombotic complications. Inclusion criteria included patients age >18 undergoing PPI for subclavian, renal or lower extremity arterial stenosis. Exclusion criteria included acute limb ischemia, use of fibrinolytic agents or GP IIb/IIIa antagonists, recent MI or CVA, and contraindication to heparin or bivalirudin. Out of 160 patients, 79 patients were dosed with heparin at 50 u/kg (goal ACT of 180 –225) and 81 patients were dosed with bivalirudin at 0.75 mcg/kg bolus followed by 1.75-mcg/kg infusion. Bivalirudin infusions were discontinued at the end of the procedure. Procedural success was defined as less than 30% post procedure residual stenosis. Major bleeding was defined as intracranial or retroperitoneal hemorrhage, or fall in Hgb ≥3 g/dl. All other bleeding was considered a minor bleed. In addition, anticoagulation cost analysis was conducted. Results: Procedural success in 100% and 96.2% patients (p=NS) (no patient suffered acute vessel occlusion or any intraprocedural thrombotic complications), major bleeding occurred in 0% and 3.7% patients (p=NS), minor bleeding occurred in 5.1% and 11% patients (p=NS), who received heparin and bivalirudin, respectively. There was no statistical difference in time to sheath removal, time-to-ambulation, and length of hospital stay. The average charge to patients for heparin was 66,whereasthechargeforbivalirudinwas66, whereas the charge for bivalirudin was 66,whereasthechargeforbivalirudinwas2727. Conclusion: Low-dose heparin is equally as safe and effective as bivalirudin in PPI. PPI with heparin is considerably more cost-effective than PPI with bivalirudin. Larger randomized studies are required to further evaluate this issue.

Ramagopal Tumuluri hasn't uploaded this paper.

Let Ramagopal know you want this paper to be uploaded.

Ask for this paper to be uploaded.